The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
Santiago Viteri Ramirez
No relevant relationships to disclose
Carlota Costa
No relevant relationships to disclose
Ana Gimenez Capitan
No relevant relationships to disclose
Susana Benlloch
No relevant relationships to disclose
Miquel Taron
No relevant relationships to disclose
Jose Javier Sanchez
No relevant relationships to disclose
Amaya Gasco
No relevant relationships to disclose
Alejandro Martinez-Bueno
No relevant relationships to disclose
Niki Karachaliou
No relevant relationships to disclose
Carlos Camps
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Enric Carcereny Costa
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Felipe Cardenal
No relevant relationships to disclose
Rut Porta
No relevant relationships to disclose
Joaquim Bosch
No relevant relationships to disclose
Ramon Palmero
No relevant relationships to disclose
Cristina Buges
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose